Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic acids: A new class of dual PPARα/γ agonists

Journal of Medicinal Chemistry

Volumn 44, Issue 13, 2001, Pages 2061-2064

  Brooks, D A ^a   Etgen, G J ^a   Rito, C J ^a   Shuker, A J ^a,c   Dominianni, S J ^a   Warshawsky, A M ^a   Ardecky, R ^b   Paterniti, J R ^b   Tyhonas, J ^b   Karanewsky, D S ^b   Kauffman, R F ^a   Broderick, C L ^a   Oldham, B A ^a   Montrose Rafizadeh, C ^a   Winneroski, L L ^a   Faul, M M ^a   McCarthy, J R ^a  

^a ELI LILLY AND COMPANY   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

^c Nutec Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 2 [4 [2 (5 METHYL 2 OXAZOL 4 YL)ETHOXY]PHENOXY]PROPIONIC ACID; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; FENOFIBRIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROPIONIC ACID DERIVATIVE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HOMEOSTASIS; MOUSE; NONHUMAN; PHARMACOPHORE;

ANIMALS; BLOOD GLUCOSE; CHOLESTEROL, HDL; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED STRAINS; PROPIONIC ACIDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 0035927439     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0155188     Document Type: Article

References (24)

1. The rising global burden of diabetes and its complications: Estimations and projections to the year 2010
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
3. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
4. The RXR heterodimers and orphan receptors
5. The PPARs: From orphan receptors to drug discovery
6. The peroxisome proliferator activated receptor-gamma is a negative modulator of macrophage activation
7. PPARgamma-LXRABCAi pathway is involved in cholesterol efflux and atherogenesis
8. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL
9. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low-density lipoprotein receptor deficient mice
10. Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents
11. Novel thiazolidine-2,4-diones as potent euglycemic agents
12. (3-Substituted-Benzyl)-thiazolidine-2,4-diones as structurally new antihyperglycemic agents
13. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative
14. The isoxazolidine-3,5-dione hypoglycemic agent JTT-501 and other nonthiazolidinedione insulin sensitizers
15. Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents
16. Peroxisome proliferatoractivated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
17. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferatoractivated receptor alpha
18. Altered fatty acid partitioning by PPAR activators improves glucose homeostasis; a case for PPARα and γ coagonists
19. Studies on azole compounds. III. Reactions of oxazole N-oxides with phosphoryl chloride and acetic anhydride
20. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
21. Opposite Regulation of Human Versus Mouse Apolipoprotein A-I by Fibrates in Human Apolipoprotein A-I Transgenic Mice
22. Peroxisome proliferatoractivated receptor a activators improve insulin sensitivity and reduce adiposity